Abstract: Disclosed herein are methods for prophylactic treatment of acute coronary syndrome (ACS) comprising administering, by inhalation, an effective amount of a pharmaceutical composition comprising at least one anticoagulant or antiplatelet agent to a subject in need thereof, wherein the anticoagulant or antiplatelet agent first enters the heart via the left atrium.
Type:
Grant
Filed:
June 2, 2020
Date of Patent:
January 10, 2023
Assignees:
InCarda Therapeutics, Inc., The Regents of the University of California
Abstract: Pharmaceutical compositions comprising an antiarrhythmic agent for treatment of a heart condition via inhalation. Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also disclosed.
Type:
Grant
Filed:
June 15, 2020
Date of Patent:
June 1, 2021
Assignee:
InCarda Therapeutics, Inc.
Inventors:
Michael Laird Hurrey, Luiz Belardinelli, Prashanti Madhavapeddi, Carlos Schuler
Abstract: Pharmaceutical compositions comprising an antiarrhythmic agent for treatment of a heart condition via inhalation. Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also disclosed.
Type:
Grant
Filed:
June 15, 2020
Date of Patent:
May 18, 2021
Assignee:
InCarda Therapeutics, Inc.
Inventors:
Michael Laird Hurrey, Luiz Belardinelli, Prashanti Madhavapeddi, Carlos Schuler
Abstract: Disclosed herein are methods, formulations, and kits for treating or preventing a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia, using selective ?1 adrenergic receptor blockers. Also disclosed herein are methods, formulations, and kits for treating a heart condition via inhalation or intranasal spray administration of selective ?1 adrenergic receptor blocker and class I antiarrhythmic agent.
Type:
Grant
Filed:
March 22, 2019
Date of Patent:
August 18, 2020
Assignee:
InCarda Therapeutics, Inc.
Inventors:
Luiz Belardinelli, Rangachari Narasimhan, Carlos Schuler
Abstract: Disclosed herein are methods for prophylactic treatment of acute coronary syndrome (ACS) comprising administering, by inhalation, an effective amount of a pharmaceutical composition comprising at least one anticoagulant or antiplatelet agent to a subject in need thereof, wherein the anticoagulant or antiplatelet agent first enters the heart via the left atrium.
Type:
Grant
Filed:
January 20, 2016
Date of Patent:
June 2, 2020
Assignees:
InCarda Therapeutics, Inc., The Regents of the University of California
Abstract: Disclosed herein are methods of treating cardiac arrhythmia with electronic monitoring in a timely manner. Also disclosed herein are systems for electronic monitoring of cardiac arrhythmia.
Type:
Grant
Filed:
March 22, 2018
Date of Patent:
May 26, 2020
Assignee:
InCarda Therapeutics, Inc.
Inventors:
Rangachari Narasimhan, Luiz Belardinelli, Carlos A. Schuler
Abstract: Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also contemplated.
Type:
Grant
Filed:
May 10, 2018
Date of Patent:
October 15, 2019
Assignee:
InCarda Therapeutics, Inc.
Inventors:
Carlos Schuler, Rangachari Narasimhan, Luiz Belardinelli, Prashanti Madhavapeddi
Abstract: Methods of treating atrial arrhythmia include administering an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof, such that the at least one antiarrhythmic pharmaceutical agent first enters the heart through the pulmonary vein to the left atrium. Other methods of treating atrial arrhythmia include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. An amount of the at least one antiarrhythmic pharmaceutical agent may peak in the coronary sinus of the heart at a time ranging from 10 seconds to 30 minutes from initiation of the administering. Unit doses, aerosols, and kits are also contemplated.
Type:
Grant
Filed:
February 26, 2015
Date of Patent:
August 14, 2018
Assignee:
InCarda Therapeutics, Inc.
Inventors:
Carlos A. Schuler, Rangachari Narasimhan
Abstract: Disclosed herein are methods of treating cardiac arrhythmia with electronic monitoring in a timely manner. Also disclosed herein are systems for electronic monitoring of cardiac arrhythmia.
Type:
Grant
Filed:
February 1, 2017
Date of Patent:
July 3, 2018
Assignee:
INCARDA THERAPEUTICS, INC.
Inventors:
Rangachari Narasimhan, Luiz Belardinelli, Carlos A. Schuler
Abstract: Methods of treating atrial arrhythmia include administering an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof, such that the at least one antiarrhythmic pharmaceutical agent first enters the heart through the pulmonary vein to the left atrium. Other methods of treating atrial arrhythmia include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. An amount of the at least one antiarrhythmic pharmaceutical agent may peak in the coronary sinus of the heart at a time ranging from 10 seconds to 30 minutes from initiation of the administering. Unit doses, aerosols, and kits are also contemplated.
Type:
Grant
Filed:
March 18, 2010
Date of Patent:
March 10, 2015
Assignee:
InCarda Therapeutics, Inc.
Inventors:
Carlos A. Schuler, Rangachari Narasimhan